PL1685849T3 - Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego - Google Patents

Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego

Info

Publication number
PL1685849T3
PL1685849T3 PL04799810T PL04799810T PL1685849T3 PL 1685849 T3 PL1685849 T3 PL 1685849T3 PL 04799810 T PL04799810 T PL 04799810T PL 04799810 T PL04799810 T PL 04799810T PL 1685849 T3 PL1685849 T3 PL 1685849T3
Authority
PL
Poland
Prior art keywords
pde
inhibitors
interstitial cystitis
treatment
pelvic pain
Prior art date
Application number
PL04799810T
Other languages
English (en)
Inventor
Miki Kobayashi
Satoshi Kubo
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1685849T3 publication Critical patent/PL1685849T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
PL04799810T 2003-11-20 2004-11-18 Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego PL1685849T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003390137 2003-11-20
PCT/JP2004/017521 WO2005049087A1 (ja) 2003-11-20 2004-11-18 慢性骨盤痛症候群治療剤
EP04799810A EP1685849B1 (en) 2003-11-20 2004-11-18 Pde 4 inhibitors for the treatment of interstitial cystitis

Publications (1)

Publication Number Publication Date
PL1685849T3 true PL1685849T3 (pl) 2012-07-31

Family

ID=34616327

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04799810T PL1685849T3 (pl) 2003-11-20 2004-11-18 Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego

Country Status (9)

Country Link
US (1) US20070167450A1 (pl)
EP (1) EP1685849B1 (pl)
JP (1) JPWO2005049087A1 (pl)
AT (1) ATE542546T1 (pl)
CA (1) CA2544322C (pl)
ES (1) ES2378374T3 (pl)
PL (1) PL1685849T3 (pl)
PT (1) PT1685849E (pl)
WO (1) WO2005049087A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
EP2292089A1 (en) 2008-01-11 2011-03-09 Astellas Pharma Inc. Model animal having both pain in testis or testis-related discomfort actions and frequent urination
CA2817290A1 (en) * 2010-11-11 2012-05-18 Josef Penninger Compounds and methods for treating pain
CN104379180A (zh) * 2012-04-10 2015-02-25 佐治亚州立大学研究基金会公司 用cyld抑制剂治疗中耳炎及其它病状的组合物和方法
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
KR970705562A (ko) * 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JPH11292878A (ja) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd イミダゾナフチリジン誘導体
JPH11292877A (ja) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd 1,4−ジ置換ピリドピラジン誘導体
EP1075535A4 (en) * 1998-05-07 2006-01-18 Univ Maryland METHOD OF DIAGNOSING AND TREATING CHRONIC PELVIC PAIN SYNDROME
AR029185A1 (es) * 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
GB0011802D0 (en) 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
KR20040052489A (ko) * 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
KR20040010713A (ko) * 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin

Also Published As

Publication number Publication date
CA2544322C (en) 2012-05-08
ES2378374T3 (es) 2012-04-11
WO2005049087A1 (ja) 2005-06-02
PT1685849E (pt) 2012-02-15
EP1685849A4 (en) 2008-12-31
EP1685849B1 (en) 2012-01-25
EP1685849A1 (en) 2006-08-02
JPWO2005049087A1 (ja) 2007-06-07
CA2544322A1 (en) 2005-06-02
US20070167450A1 (en) 2007-07-19
ATE542546T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
DE122007000056I1 (de) Beta-amino-tetrahydroimidazo (1,2-A)pyrazine und-tetrahydrotriazolo(4,3-A)pyrazine als dipeptidyl peptidase Inhibitoren zur Behandlung oder preventionvon Diabetes
PL1983000T3 (pl) Sposób leczenia stwardnienia rozsianego przez hamowanie aktywności IL-17
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
IL144144A0 (en) Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
PT1470120E (pt) Derivados n-óxidos de n-fenil-2-pirimidino-amina
ATE465756T1 (de) Antitumoreffekt-verstärker
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
DE602004025708D1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
GB0226434D0 (en) Combination product
ITTO20021024A1 (it) Trattamento di superficie per componenti ferrosi.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
PL368271A1 (pl) Sposób leczenia i zapobiegania bólowi i zapaleniuglukozaminą i inhibitorem selektywnym cyklooksygenazy-2 i kompozycje je zawierające
PL1685849T3 (pl) Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
WO2003053365A3 (en) Syn3 compositions and methods
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
ZA200308172B (en) Use of IL-18 inhibitors for treating or preventing CNS injuries.
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
MXPA05010800A (es) Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos.